RhoVac Reports to Mount Sinai Hospital in New York Join Phase IIb Study in Prostate Cancer
The participation of Mount Sinai was directly caused by the FDA approval of RhoVac's Fast Track Designation.
The participation of Mount Sinai was directly caused by the FDA approval of RhoVac's Fast Track Designation.
Copyright 2025 | All Rights Reserved | Medical Device News Magazine, is a Division of PTM Healthcare Marketing, Inc.